iPLA2 Inhibitors

Chemical inhibitors of iPLA2 target the enzyme's ability to hydrolyze phospholipids by various mechanisms of action. Bromoenol lactone and its derivatives, including (S)-Bromoenol lactone and (R)-Bromoenol lactone, inhibit iPLA2 by irreversibly binding to the active site serine. This covalent attachment impedes the enzyme's catalytic activity, precluding the cleavage of fatty acids from glycerophospholipids. Similarly, FKGK11 inhibits iPLA2 by binding to the enzyme's catalytic domain, obstructing the interaction between iPLA2 and its lipid substrates, thus inhibiting the lipid hydrolysis process. MJ33 follows a comparable route by directly interacting with the active site, which leads to an inhibition of the phospholipid substrate hydrolysis.Another compound, Efipladib, achieves inhibition by occupying the active site of iPLA2, effectively blocking the entrance of substrates and thwarting the enzyme's hydrolytic action. Palmitoyl trifluoromethyl ketone functions through a similar mechanism, by alkylating the catalytic dyad of iPLA2, which is a crucial component of the enzyme's hydrolysis reaction. Propranolol, on the other hand, indirectly inhibits iPLA2 not by directly interacting with the active site, but by interfering with upstream signaling pathways that regulate the activation of iPLA2, leading to a decrease in its enzymatic activity. AVX 001 specifically binds to and inhibits iPLA2, preventing the enzyme from performing its role in the cleavage of fatty acids from glycerophospholipids. The inhibition strategies employed by these chemicals collectively ensure the functional inhibition of iPLA2, each obstructing the enzyme's activity through distinct yet definitive interactions with either the active site or relevant regulatory pathways.